Feld R, Evans W K, DeBoer G, Quirt I C, Shepherd F A, Yeoh J L, Pringle J F, Payne D G, Herman J G, Chamberlain D
J Clin Oncol. 1984 Apr;2(4):294-304. doi: 10.1200/JCO.1984.2.4.294.
One hundred fifty-three patients with limited and 167 with extensive small cell carcinoma of the lung (SCCL) were evaluable for response to treatment with six courses of chemotherapy (cyclophosphamide, doxorubicin, and vincristine), irradiation to intrathoracic disease, and prophylactic cranial irradiation (PCI). No maintenance chemotherapy was given. Fifty-two percent of patients with limited disease (LD) and 10% of extensive disease patients (ED) achieved a complete response. The median survival times for LD and ED patients were 49 and 34 weeks, respectively. These results were compared to a previous experience with 147 patients who were treated with three courses of similar induction chemotherapy and thoracic irradiation, as well as one year of maintenance chemotherapy (CCNU, procarbazine, and methotrexate) but without PCI. Although the use of PCI was found to reduce the frequency of brain metastases as the site of first relapse, detailed comparisons of response rates and survival showed no significant differences between the two study populations. Prolonged maintenance chemotherapy of the type used in the first study does not favorably influence outcome after intensive induction therapy for SCCL.
153例局限性和167例广泛性肺小细胞癌(SCCL)患者可评估对六个疗程化疗(环磷酰胺、阿霉素和长春新碱)、胸部疾病放疗及预防性颅脑照射(PCI)的治疗反应。未给予维持化疗。局限性疾病(LD)患者中有52%、广泛性疾病(ED)患者中有10%达到完全缓解。LD和ED患者的中位生存时间分别为49周和34周。将这些结果与之前147例患者的经验进行比较,这些患者接受了三个疗程类似的诱导化疗和胸部放疗,以及一年的维持化疗(洛莫司汀、丙卡巴肼和甲氨蝶呤),但未接受PCI。尽管发现使用PCI可降低脑转移作为首次复发部位的频率,但反应率和生存率的详细比较显示,两个研究人群之间无显著差异。第一项研究中使用的延长维持化疗对SCCL强化诱导治疗后的结局无有利影响。